{'fraction_non_alphanumeric': 0.03197158081705151, 'fraction_numerical': 0.008880994671403197, 'mean_word_length': 5.337078651685394, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?

Dear Editor, Bone marrow (BM) evaluation is mandatory to decide remis‐ sion or relapse of acute myeloid leukemia (AML).1 A diagnosis of relapsed AML requires the presence of 5% leukemic cells or more on BM morphologic evaluation, and AML relapses in approximately two‐thirds of patients even though leukemic cells are less than 5% in BM.1,2 Multimodal approaches for minimal residual disease (MRD) are performed to predict early relapse, including flow cytometric,